Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | Non-Final OA | Genzyme Corporation |
| 17642515 | IMMUNOACTIVE MICROPARTICLES AND USES THEREOF | Final Rejection | The Regents of the University of California |
| 17638519 | IMPLANTABLE SCAFFOLDS AND USES THEREOF FOR IMMUNOTHERAPY AND OTHER USES | Final Rejection | The Regents of the University of California |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | Final Rejection | Eberhard Karls Universität Tübingen |
| 17257764 | METHODS AND COMPOSITIONS FOR MODULATING MYELOPEROXIDASE (MPO) EXPRESSION | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 17425130 | WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF | Non-Final OA | CHILDREN'S NATIONAL MEDICAL CENTER |
| 17189970 | MOBILIZED PERIPHERAL BLOOD AS A SOURCE OF MODIFIED IMMUNE CELLS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17045467 | THERAPEUTIC TARGETING OF ONCOGENES USING EXOSOMES | Non-Final OA | Board of Regents, The University of Texas System |
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | Final Rejection | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18036620 | BIPHASIC SUBCUTANEOUS DOSING REGIMENS FOR ANTI-VLA-4 ANTIBODIES | Non-Final OA | BIOGEN MA INC. |
| 17633255 | METHOD OF TREATING KELOIDS | Final Rejection | Icahn School of Medicine at Mount Sinai |
| 17624541 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND RELATED METHODS | Final Rejection | ZYMEWORKS BC INC. |
| 18597711 | ANTI-CD20 ANTIBODY COMPOSITIONS | Final Rejection | Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
| 18597659 | ANTI-CD20 ANTIBODY COMPOSITIONS | Final Rejection | Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
| 18065462 | BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS | Non-Final OA | Xencor, Inc. |
| 17632181 | TREATMENT OF CANCER WITH A COMBINATION OF AN ANTIBODY THAT BINDS LGR5 AND EGFR AND A TOPOISOMERASE I INHIBITOR | Final Rejection | Merus N.V. |
| 18016331 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | Non-Final OA | PINOTBIO, INC. |
| 18013523 | MULTISPECIFIC BINDING PROTEIN OF IMMUNE CELL ENGAGER, PREPARATION THEREFOR AND APPLICATION THEREOF | Non-Final OA | Nona Biosciences (Shanghai) Co., Ltd. |
| 17623710 | ANTI-CD154 ANTIBODIES AND USES THEREOF | Non-Final OA | TONIX PHARMA LIMITED |
| 18022778 | NUCLEIC ACIDS ENCODING A POLYPEPTIDE COMPRISING A MODIFIED FC REGION OF A HUMAN IGG1 AND AT LEAST ONE HETEROLOGOUS ANTIGEN | Non-Final OA | Scancell Limited |
| 17619569 | ULTRAMODULAR IGG3-BASED SPACER DOMAIN AND MULTI-FUNCTION SITE FOR IMPLEMENTATION IN CHIMERIC ANTIGEN RECEPTOR DESIGN | Final Rejection | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG |
| 17040109 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | Final Rejection | UNIVERSITÉ D'AIX MARSEILLE |
| 17613392 | ANTI-HEPATITIS B VIRUS ANTIBODIES AND USE THEREOF | Non-Final OA | YANG SHENG TANG COMPANY, LTD. |
| 17057060 | CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND USES THEREOF | Non-Final OA | BIOSCEPTRE (UK) LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy